Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Castle Biosciences ( (CSTL) ) just unveiled an update.
On August 4, 2025, Castle Biosciences reported its second-quarter financial results, highlighting a revenue of $86 million and a 33% increase in total test reports for its core products compared to the previous year. Despite challenges such as the Novitas LCD affecting certain test coverages and the discontinuation of IDgenetix, the company raised its full-year revenue guidance to $310-320 million. The company also announced strategic moves including a tuck-in acquisition and a collaboration with SciBase, aiming to support long-term value creation. Additionally, the DecisionDx-Melanoma test received Breakthrough Device designation from the FDA, with studies showing a 32% reduction in mortality risk for patients using the test.
The most recent analyst rating on (CSTL) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL Stock Forecast page.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.
Castle Biosciences showcases strong financial performance and positive developments in recent earnings and corporate events. However, technical analysis indicates bearish momentum, and valuation metrics suggest caution due to negative P/E ratio and lack of dividend. Overall, while the company is strategically positioned for growth, current market sentiment reflects some underlying risks.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
Castle Biosciences, Inc. is a company focused on improving health through innovative diagnostic tests that guide patient care. It operates primarily in the field of dermatology and oncology, with key products including DecisionDx®-Melanoma and TissueCypher®. The company is positioned to leverage its expertise in gene expression profiling to enhance patient outcomes and has a market focus on providing valuable insights for clinicians and patients.
Average Trading Volume: 436,236
Technical Sentiment Signal: Sell
Current Market Cap: $423M
For detailed information about CSTL stock, go to TipRanks’ Stock Analysis page.